| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| CD6 | HOTAvitag CD6-H82E3 | Biotinylated Human CD6 Protein, His,Avitag™ (MALS verified) |  Human | HEK293 |  | MALSSDS-PAGE | $360.00 25ug | |
| CD6 | HOT CD6-H52H7 | Human CD6 / TP120 Protein, His Tag | Human | HEK293 |  | SDS-PAGE | $340.00 100ug | |
| CD6 | Cynomolgus CD6 Protein, His Tag (MALS verified) |  Cynomolgus | HEK293 |  | MALSSDS-PAGE | $395.00 100ug | ||
| CD6 | Avitag CD6-C82E3 | Biotinylated Cynomolgus CD6 Protein, His,Avitag™ (MALS verified) | Cynomolgus | HEK293 |  | MALSSDS-PAGE | $360.00 25ug | |
| CD6 | Avitag CD6-C82F3 | Biotinylated Cynomolgus CD6 / TP120 Protein, Fc,Avitag™ (MALS verified) | Cynomolgus | HEK293 |  | MALSSDS-PAGE | $360.00 25ug | |
| CD6 | Avitag CD6-H82F3 | Biotinylated Human CD6 / TP120 Protein, Fc,Avitag™ (MALS verified) | Human | HEK293 |  | MALSSDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells therapy (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Diabetes Mellitus, Type 1; Graft vs Host Disease; Hemic and Lymphatic Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Itolizumab | T-1-hT; EQ-001; T-1-h; h-T1; Bmab-600; Bmab600 | Approved | Center Of Molecular Immunology | Alzumab | India | Plaque psoriasis | Biocon Ltd | 2013-01-01 | Asthma; Coronavirus Disease 2019 (COVID-19); Dermatomyositis; Graft vs Host Disease; Lupus Erythematosus, Cutaneous; Lupus Nephritis; Plaque psoriasis; Psoriasis; Respiratory Distress Syndrome, Adult | Details |
